Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.51 |
| ▸ | PDE5A | O76074 | 2/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31069507 | 0.81 | GPBAR1 (0.48) | GPBAR1 | |
| SCHEMBL14894321 | 0.79 | SLC22A12 (0.51) | SLC22A12PDE5ACYP1A2CYP3A4HSD17B10 | |
| SCHEMBL14894443 | 0.79 | SLC22A12 (0.51) | SLC22A12PDE5ACYP1A2CYP3A4HSD17B10 | |
| SCHEMBL6269721 | 0.79 | HTR1A (0.56) | ALDH1A1HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL15631640 | 0.79 | ACHE (0.43) | CYP1A2CYP3A4ALDH1A1TDP1GSK3B | |
| SCHEMBL19998594 | 0.79 | LIMK1 (0.43) | CYP1A2CYP3A4ALDH1A1TDP1GSK3B | |
| SCHEMBL15618394 | 0.78 | USP30 (0.41) | GCGRGSK3BPOLBSMN1; SMN2TP53 | |
| SCHEMBL17032402 | 0.78 | AMY1A (0.44) | ALDH1A1GSK3BGAAMEN1TSHR | |
| SCHEMBL18516342 | 0.77 | HTR1A (0.54) | ALDH1A1HTR1AHTR1DHTR1BHTR2A | |
| SCHEMBL28590507 | 0.77 | ENPP2 (0.50) | SLC22A12PDE5ACYP1A2CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| EP-3277677-B9 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-07-14 | — | — | EP | disclosed |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| EP-3842427-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2021-06-30 | — | — | EP | disclosed |
| EP-3277677-B1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-02-24 | — | — | EP | disclosed |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | US | disclosed |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| US-20190270708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | Missions Therapeutics Limited (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | SLC22A12 4193/4885PDE5A 1573/4885GCGR 4438/4885 |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | SLC22A12 3774/4885PDE5A 1243/4885GCGR 4593/4885 |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | SLC22A12 3774/4885PDE5A 1243/4885GCGR 4593/4885 |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | SLC22A12 4119/4885PDE5A 1151/4885GCGR 4582/4885 |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | SLC22A12 4193/4885PDE5A 1573/4885GCGR 4438/4885 |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | SLC22A12 3774/4885PDE5A 1243/4885GCGR 4593/4885 |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | SLC22A12 3774/4885PDE5A 1243/4885GCGR 4593/4885 |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | SLC22A12 3774/4885PDE5A 1243/4885GCGR 4593/4885 |
| US-20190270708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | SLC22A12 3774/4885PDE5A 1243/4885GCGR 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.